Median Technologies (ALMDT.PA)

Executive Summary

Median Technologies is a French pioneer in AI-powered medical imaging for oncology, combining a Software as a Medical Device (SaMD) platform with imaging services for clinical trials. Its flagship product, e-lynx, leverages deep learning to detect early-stage lung cancer from CT scans, addressing a critical need for non-invasive, accurate screening. The company also offers iCRO services to pharmaceutical sponsors, providing centralized image analysis to accelerate drug development. With a strong intellectual property portfolio and regulatory approvals in Europe (CE marking) and ongoing submissions for FDA clearance, Median is positioned to capture growth in the expanding AI diagnostics market. The company has secured commercial contracts with leading hospitals and research institutions, validating its technology and driving recurring revenue. Recent data from real-world studies demonstrate e-lynx's ability to reduce false positives and improve radiologist efficiency. Looking ahead, Median is focused on expanding its product pipeline to other cancer types and scaling its CRO business. With a lean cost structure and a clear path to profitability, the company represents a high-upside opportunity in the AI health-tech space. A successful FDA clearance expected in 2026 would unlock the large US market, potentially doubling the addressable opportunity.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) clearance for e-lynx lung cancer screening algorithm70% success
• Q3 2026Multi-year imaging services agreement with a top-10 pharmaceutical company60% success
• Q4 2026Publication of pivotal clinical validation study for e-lynx in a major peer-reviewed journal80% success